Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management
- PMID: 32856980
- DOI: 10.1097/JU.0000000000001337
Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management
Abstract
Purpose: Current serum tumor markers for testicular germ cell tumor are limited by low sensitivity. Growing evidence supports the use of circulating miR-371a-3p as a superior marker for malignant (viable) germ cell tumor management. We evaluated the real-world application of serum miR-371a-3p levels in detecting viable germ cell tumor among patients undergoing partial or radical orchiectomy.
Materials and methods: Serum samples were collected from 69 consecutive patients before orchiectomy. Performance characteristics of serum miR-371a-3p were compared with conventional serum tumor markers (⍺-fetoprotein/β-human chorionic gonadotropin/lactate dehydrogenase) between patients with viable germ cell tumor and those without viable germ cell tumor on orchiectomy pathology. Relative miR-371a-3p levels were correlated with clinical course. The Kruskal-Wallis test and linear and ordinal regression models were used for analysis.
Results: For detecting viable germ cell tumor, combined conventional serum tumor markers had a specificity of 100%, sensitivity of 58% and AUC of 0.79. The miR-371a-3p test showed a specificity of 100%, sensitivity of 93% and AUC of 0.978. Median relative expression of miR-371a-3p in viable germ cell tumor cases was more than 6,800-fold higher than in those lacking viable germ cell tumor. miR-371a-3p levels correlated with composite stage (p=0.006) and, among composite stage I cases, independently associated with embryonal carcinoma percentage (p=0.0012) and tumor diameter (p <0.0001). Six patients underwent orchiectomy after chemotherapy and were correctly predicted to have presence or absence of viable germ cell tumor by the miR-371a-3p test.
Conclusions: If validated, the miR-371a-3p test can be used in conjunction with conventional serum tumor markers to aid clinical decision making. A positive miR-371a-3p test in patients after preoperative chemotherapy or with solitary testes could potentially guide subsequent orchiectomy or observation.
Keywords: biomarkers; germ cell and embryonal; microRNAs; neoplasms; testicular neoplasms.
Comment in
-
Editorial Comment.J Urol. 2021 Jan;205(1):143-144. doi: 10.1097/JU.0000000000001337.01. Epub 2020 Nov 12. J Urol. 2021. PMID: 33179578 No abstract available.
Similar articles
-
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.J Clin Oncol. 2019 Jun 1;37(16):1412-1423. doi: 10.1200/JCO.18.01480. Epub 2019 Mar 15. J Clin Oncol. 2019. PMID: 30875280 Free PMC article.
-
Micro-RNA-371a-3p in Germ Cell Testicular Tumors on Diagnosis: A Prospective Case-Control Study in Turkish Population.Urol J. 2024 Jun 9;21(4):242-249. doi: 10.22037/uj.v20i.8002. Urol J. 2024. PMID: 38629199
-
MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.Andrology. 2015 Jan;3(1):78-84. doi: 10.1111/j.2047-2927.2014.00269.x. Epub 2014 Sep 4. Andrology. 2015. PMID: 25187505
-
Potential next generation markers of testicular germ cell tumors: miRNA-371a-3p.Int Urol Nephrol. 2025 Mar;57(3):691-700. doi: 10.1007/s11255-024-04284-2. Epub 2024 Nov 22. Int Urol Nephrol. 2025. PMID: 39576421 Review.
-
The present and future of serum diagnostic tests for testicular germ cell tumours.Nat Rev Urol. 2016 Dec;13(12):715-725. doi: 10.1038/nrurol.2016.170. Epub 2016 Oct 18. Nat Rev Urol. 2016. PMID: 27754472 Review.
Cited by
-
Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses.Eur Urol Open Sci. 2024 Aug 17;68:1-9. doi: 10.1016/j.euros.2024.08.003. eCollection 2024 Oct. Eur Urol Open Sci. 2024. PMID: 39257620 Free PMC article.
-
DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies From Testicular Germ Cell Tumor Patients.Front Oncol. 2022 Jun 10;12:876732. doi: 10.3389/fonc.2022.876732. eCollection 2022. Front Oncol. 2022. PMID: 35756620 Free PMC article.
-
Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers.Cancers (Basel). 2024 Mar 31;16(7):1379. doi: 10.3390/cancers16071379. Cancers (Basel). 2024. PMID: 38611057 Free PMC article. Review.
-
Liquid Biopsies in the Clinical Management of Germ Cell Tumor Patients: State-of-the-Art and Future Directions.Int J Mol Sci. 2021 Mar 6;22(5):2654. doi: 10.3390/ijms22052654. Int J Mol Sci. 2021. PMID: 33800799 Free PMC article. Review.
-
Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range.Res Sq [Preprint]. 2023 Mar 21:rs.3.rs-2644890. doi: 10.21203/rs.3.rs-2644890/v1. Res Sq. 2023. Update in: Sci Rep. 2023 Jun 29;13(1):10558. doi: 10.1038/s41598-023-37271-1. PMID: 36993198 Free PMC article. Updated. Preprint.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical